Rectal drug delivery system and preparation method thereof
By adopting a three-layer structure rectal delivery system, using water-soluble membrane layer and emulsion-form matrix, the problem of drug leakage and single load in traditional systems is solved, the bioavailability and sustained release effect are improved, and the treatment of complex diseases is met need.
Patent Information
- Application Number
- CN202411085402.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-08
- Publication Date
- 2024-11-15
AI Technical Summary
Traditional rectal drug delivery systems have problems such as rapid melting of oily matrix, causing oil leakage, single drug load, and difficulty in meeting the treatment of complex diseases and leading to poor absorption of drugs due to rectal physiological characteristics.
The rectal drug delivery system adopts a three-layer structure, including the outer water-soluble membrane structure, the middle O/W structure and the inner W/O structure, and uses water-soluble materials and emulsion-form matrix to improve the bioavailability of drugs and The sustained release effect meets different clinical needs.
It improves the bioavailability of the drug and patient compliance, extends the drug action time, avoids drug leakage and intestinal dryness, and achieves layer-by-layer release and long-term sustained release of a variety of drugs, meeting the treatment needs of complex diseases.
Smart Images

Figure CN118948740A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of pharmaceutical preparations, and in particular to a rectal drug delivery system and a preparation method thereof. Background Art
[0002] As a non-oral drug delivery form, the rectal drug delivery system overcomes some unavoidable deficiencies of oral preparations, making the drug less or not damaged by gastrointestinal pH or enzymes, avoiding drug irritation to the gastric mucosa, avoiding the first-pass effect of the liver, and being suitable for patients who are inconvenient to take drugs orally. The rectal drug delivery system can be used for local treatment, such as suppositories for the treatment of hemorrhoids, and can also be used for systemic drug delivery, such as antipyretic suppositories. The rectal drug delivery system has the advantages of large drug contact area and rapid onset of action, which can improve the bioavailability of drugs.
[0003] However, the traditional rectal drug delivery system has the following problems: (1) Most traditional rectal drug delivery systems are based on oily matrices. After being injected into the body, the oily matrix melts quickly, which can easily cause the oil to leak out of the body, reduce the efficacy, and cause poor patient compliance; (2) The traditional rectal drug delivery system can only carry a single type of drug, which cannot meet the needs of complex conditions. For example, for the treatment of diseases that require medication adjustment according to the treatment process, patients need to constantly adjust the type of medication and repeatedly administer the drug, which increases the patient's treatment burden; (3) The rectum has specific physiological characteristics: for example, the buffering capacity of rectal fluid is low, and drug administration can easily cause changes in the pH value of the rectum; in addition, the presence of feces will also affect drug dissolution and the contact between the drug and the mucosa, and there is a mucus layer about 100 μm thick on the rectal epithelial layer, which hinders drug absorption and affects the efficacy of the drug. Summary of the invention
[0004] Based on this, it is necessary to provide a rectal drug delivery system and a preparation method thereof to solve the above technical problems.
[0005] The first aspect of the present application provides a rectal drug delivery system, which includes a water-soluble film layer structure located in the outer layer, an O / W structure located in the middle layer, and a W / O structure located in the inner layer; the water-soluble film layer structure includes a water-soluble material; the O / W structure includes a second active pharmaceutical ingredient and an O / W emulsion matrix; and the W / O structure includes a third active pharmaceutical ingredient and a W / O emulsion matrix.
[0006] In some embodiments, the water-soluble film layer structure further includes a first pharmaceutically active ingredient, and the mass ratio of the first pharmaceutically active ingredient to the water-soluble material is 1:(1.5-20).
[0007] In some embodiments, the water-soluble film layer structure further includes a release enhancer, and the weight ratio of the release enhancer to the first pharmaceutical active ingredient in the water-soluble film layer structure is (0.03-0.1):1.
[0008] In some embodiments, the rectal drug delivery system is used in the preparation of systemic therapeutic drugs or local therapeutic drugs.
[0009] The rectal drug delivery system of the present application can be used for local treatment such as complicated hemorrhoids, and can also be used for systemic treatment such as pain treatment, especially migraine treatment, etc. When used for local treatment, the active ingredients of each layer of the drug are different, and the drug can be reasonably selected according to the symptoms and course of the disease, so that multiple drugs can be released layer by layer to meet different clinical needs; when used for systemic treatment, the active ingredients of each layer of the drug can be the same or different, which can achieve a long-term sustained-release therapeutic effect, extend the medication interval, and improve patient compliance.
[0010] In some embodiments, the first active pharmaceutical ingredient includes at least one of polymyxin B, benzocaine, lidocaine, pramoxine, indomethacin, furazolidone, caffeine, metoclopramide, pandoridone, clonidine, dexmedetomidine, acetaminophen, magnesium sulfate, dexamethasone, methylprednisolone, hydrocortisone and prednisone; the second active pharmaceutical ingredient includes at least one of sophora japonica, fructus aurantii, phellodendron chinense, bezoar, aspirin, naproxen, dimethoate, phenoxyethanol, chloramphenicol ... The active ingredient of the third drug includes at least one of chlorfenapyr, ibuprofen, indomethacin, acetaminophen, rofecoxib, fentanyl, methadone, buprenorphine, codeine, carbamazepine, gabapentin, and pregabalin; the active ingredient of the third drug includes at least one of bletilla striata, gallnut, white ampel, acetaminophen, sumatriptan, aspirin, ibuprofen, indomethacin, diclofenac, naproxen, rofecoxib, carbamazepine, gabapentin, and pregabalin.
[0011] In some embodiments, the O / W emulsion matrix includes an oil-soluble matrix, a water-soluble matrix and an O / W emulsifier, and the mass ratio of the oil-soluble matrix, the water-soluble matrix and the O / W emulsifier in the O / W emulsion matrix is 1:(1.2-5):(0.01-0.2).
[0012] In some embodiments, the O / W emulsion matrix further includes a sustained-release agent, and the mass ratio of the oil-soluble matrix, the water-soluble matrix, the sustained-release agent and the O / W emulsifier in the O / W emulsion matrix is 1:(1.5-5):(0.01-0.5):(0.02-0.1).
[0013] In some embodiments, the W / O emulsion matrix includes an oil-soluble matrix, a water-soluble matrix and a W / O emulsifier, and the mass ratio of the oil-soluble matrix, the water-soluble matrix and the W / O emulsifier in the W / O emulsion matrix is 1:(0.1-0.9):(0.01-0.2).
[0014] In some embodiments, the mass ratio of the first pharmaceutically active ingredient to the water-soluble material is 1:(1.5-20).
[0015] In some embodiments, the mass ratio of the second pharmaceutically active ingredient to the O / W emulsion base is 1:(1-15).
[0016] In some embodiments, the mass ratio of the third pharmaceutically active ingredient to the W / O emulsion base is 1:(1-20).
[0017] In some embodiments, the mass ratio of the water-soluble film layer structure, the O / W structure, and the W / O structure is 1:(10-20):(5-12).
[0018] The second aspect of the present application provides a method for preparing the rectal drug delivery system provided by the first aspect, and the preparation method comprises the following steps: premixing a second active pharmaceutical ingredient and an O / W emulsion matrix, heating and melting the mixture, and injecting the mixture into a mold, and extracting the mold core after cooling and solidification to obtain an O / W structure with an inner cavity; premixing a third active pharmaceutical ingredient and a W / O emulsion matrix, heating and melting the mixture, and adding the mixture into the inner cavity of the O / W structure, cooling and solidifying the mixture to form a W / O structure, and demolding the mixture to obtain an intermediate; premixing a first active pharmaceutical ingredient and a water-soluble material, and dissolving the mixture in distilled water, or dissolving the water-soluble material in distilled water, and coating the intermediate with the obtained coating solution to form a water-soluble film layer structure to obtain a rectal drug delivery system.
[0019] Compared with the conventional technology, the rectal drug delivery system provided by the present application has at least the following beneficial effects:
[0020] (1) The W / O structure in the inner layer is easy to shape and serves as the inner core support of the preparation to ensure the stability of the preparation structure. Under the protection of the outer water-soluble film structure and the middle O / W structure, the oily matrix of the inner W / O structure is prevented from melting at high temperatures, which reduces storage troubles and improves patient compliance.
[0021] (2) This preparation has a three-layer structure. Compared with ordinary double-layer suppositories, it increases the types of drugs that can be loaded, avoids drug interactions, improves drug compatibility, and can provide different drug release behaviors to achieve the best therapeutic effect and meet different clinical needs. The outer water-soluble film structure can dissolve quickly and improve bioavailability. The middle and inner layers are both emulsion matrices, which have the effect of increasing drug loading. The middle layer O / W structure can prolong the drug action time to meet the long-term treatment needs of chronic diseases.
[0022] (3) The water-soluble membrane structure located in the outer layer dissolves quickly, bonding the preparation to the inner wall of the rectum to prevent the preparation from slipping out due to physiological activities. The O / W structure located in the middle layer provides a sustained release effect for drugs with high drug loading, avoiding excessive local concentration due to sudden release, causing a sharp change in the pH of the physiological environment, and thus causing an irritation reaction. The W / O structure located in the inner layer has a certain intestinal lubrication effect due to the high oil phase ratio, and can avoid discomfort caused by intestinal dryness after the drug release is completed. As the drug is released step by step, each layer of the structure is successively degraded and absorbed by itself, without the need for patient treatment. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1 A schematic flow chart of a method for preparing a rectal drug delivery system according to an embodiment of the present application.
[0024] Figure 2 A schematic structural diagram of a mold of a rectal drug delivery system provided in one embodiment of the present application.
[0025] Figure 3 This is a graph showing the cumulative dissolution of the first active pharmaceutical ingredient of the water-soluble film layer structure of the rectal drug delivery system provided in Examples 1 to 3 of the present application.
[0026] Figure 4 This is a graph showing the cumulative dissolution of the second active pharmaceutical ingredient of the O / W structure of the rectal drug delivery system provided in Examples 1 to 3 of the present application.
[0027] Figure 5 This is a graph showing the cumulative dissolution of the third active pharmaceutical ingredient of the W / O structure of the rectal drug delivery system provided in Examples 1 to 3 of the present application.
[0028] Figure 6 This is a graph showing the cumulative dissolution of the first active pharmaceutical ingredient of the water-soluble film layer structure of the rectal drug delivery system provided in Examples 3 and 8 of the present application.
[0029] Figure 7 This is a graph showing the cumulative dissolution of acetaminophen in the rectal drug delivery system provided in Example 9 of the present application.
[0030] Reference numerals:
[0031] 1. Mould; 11. Outer jacket; 12. Injection port; 13. Mould core. DETAILED DESCRIPTION
[0032] References to embodiments of the present invention will now be provided in detail, one or more examples of which are described below. Each example is provided as an explanation rather than a limitation of the present invention. In fact, it will be apparent to those skilled in the art that various modifications and variations may be made to the present invention without departing from the scope or spirit of the present invention. For example, a feature illustrated or described as part of one embodiment may be used in another embodiment to produce a further embodiment.
[0033] Therefore, it is intended that the present invention covers such modifications and variations that fall within the scope of the appended claims and their equivalents. Other objects, features and aspects of the present invention are disclosed in or are obvious from the following detailed description. Those of ordinary skill in the art will appreciate that this discussion is only a description of exemplary embodiments and is not intended to limit the broader aspects of the present invention.
[0034] In the present invention, the technical features described in an open manner include closed technical solutions composed of the listed features, and also include open technical solutions containing the listed features.
[0035] In the present invention, when it comes to numerical ranges, unless otherwise specified, the above numerical ranges are deemed to be continuous and include the minimum and maximum values of the range, as well as each value between such minimum and maximum values. Further, when a range refers to an integer, each integer between the minimum and maximum values of the range is included. In addition, when multiple ranges are provided to describe features or characteristics, the ranges can be merged. In other words, unless otherwise specified, all ranges disclosed herein should be understood to include any and all subranges included therein.
[0036] The first aspect of the present application provides a rectal drug delivery system, which includes a water-soluble film layer structure located in the outer layer, an O / W structure located in the middle layer, and a W / O structure located in the inner layer. The water-soluble film layer structure includes a water-soluble material. The O / W structure includes a second active pharmaceutical ingredient and an O / W emulsion matrix. The W / O structure includes a third active pharmaceutical ingredient and a W / O emulsion matrix.
[0037] It is understandable that the rectal drug delivery system provided by the present application, the middle layer and the inner layer both include an emulsion type matrix. Compared with the traditional suppositories of water-soluble matrix, the emulsion type matrix can avoid the irritation of the rectal mucosa caused by the simple use of water-soluble matrix materials with strong hygroscopicity. Compared with the traditional oil-soluble matrix suppositories, the introduction of the aqueous phase avoids the drug leakage and greasy feeling caused by the rapid dissolution of the oily matrix. Compared with the traditional hydrogel suppositories, the emulsion type structure is more rigid, avoiding the defect that the suppository is not easy to form at room temperature due to the viscosity of the gel.
[0038] In some embodiments, the water-soluble material is selected from one or more of polyvinyl alcohol (PVA), hydroxypropyl methylcellulose (HPMC), polyethylene glycol (PEG), water-soluble chitosan, polyoxyethylene stearate and their derivatives; preferably a mixture of polyvinyl alcohol (PVA) and polyethylene glycol (PEG) or a mixture of hydroxypropyl methylcellulose (HPMC) and polyethylene glycol (PEG), in which the weight ratio of polyvinyl alcohol (PVA) to polyethylene glycol (PEG) is 1: (1-10), and the weight ratio of hydroxypropyl methylcellulose (HPMC) to polyethylene glycol (PEG) is 1: (1-10).
[0039] In some embodiments, the water-soluble film layer structure further includes a first pharmaceutically active ingredient, and the mass ratio of the first pharmaceutically active ingredient to the water-soluble material is 1:(1.5-20).
[0040] The water-soluble film layer structure can dissolve quickly, and the first active pharmaceutical ingredient can include a poorly soluble drug such as benzocaine, which can be released quickly, thereby improving bioavailability and quickly exerting pharmacological effects.
[0041] It can be understood that the first active pharmaceutical ingredient, the second active pharmaceutical ingredient and the active pharmaceutical ingredient are the same as or different from each other. The rectal drug delivery system of the present application can be used for local treatment or systemic treatment, and the type of active pharmaceutical ingredient can be selected according to the specific situation.
[0042] In some embodiments, the water-soluble film layer structure also includes a release enhancer, and the weight ratio of the release enhancer to the first pharmaceutical active ingredient in the water-soluble film layer structure is (0.03-0.1):1, including but not limited to 0.03:1, 0.04:1, 0.05:1, 0.06:1, 0.07:1, 0.08:1, 0.09:1, and 0.1:1.
[0043] In some embodiments, the release-enhancing agent is selected from one or more of triethyl citrate, tributyl citrate, sodium dodecyl sulfate (SDS), urea and derivatives thereof.
[0044] In some embodiments, the rectal drug delivery system is used in the preparation of systemic therapeutic drugs or local therapeutic drugs.
[0045] In some embodiments, the first active pharmaceutical ingredient includes at least one of polymyxin B, benzocaine, lidocaine, pramoxine, indomethacin, furazolidone, caffeine, metoclopramide, pandoridone, clonidine, dexmedetomidine, acetaminophen, magnesium sulfate, dexamethasone, methylprednisolone, hydrocortisone and prednisone; the second active pharmaceutical ingredient includes at least one of sophora japonica fruit, fructus aurantii, phellodendron chinense, bezoar, aspirin, naproxen, At least one of diclofenac, ibuprofen, indomethacin, acetaminophen, rofecoxib, fentanyl, methadone, buprenorphine, codeine, carbamazepine, gabapentin, and pregabalin; the third drug active ingredient includes at least one of Bletilla striata, Galla chinensis, Ampelopsis pilosula, acetaminophen, sumatriptan, aspirin, ibuprofen, indomethacin, diclofenac, naproxen, rofecoxib, carbamazepine, gabapentin, and pregabalin.
[0046] In some embodiments, the rectal drug delivery system is used to prepare a topical therapeutic agent.
[0047] In some embodiments, in the preparation of a rectal drug delivery system for the treatment of hemorrhoids, the first active pharmaceutical ingredient includes at least one of polymyxin B, benzocaine, lidocaine, pramoxine, indomethacin and furazolidone, the second active pharmaceutical ingredient includes at least one of Sophora japonica, Fructus Aurantii Immaturus, Phellodendron chinense and Bezoar, and the third active pharmaceutical ingredient includes at least one of Bletilla striata, Galla chinensis and Ampelopsis pilosula.
[0048] Clinical manifestations of hemorrhoids include bleeding, prolapse, edema and pain. Commonly used therapeutic drugs include local anesthetics, antibiotics, anti-inflammatory drugs, and compound prescriptions of Chinese medicine or plant extracts. Chemical drugs take effect quickly, but long-term use has obvious side effects. For example, long-term use of anti-inflammatory corticosteroids may cause immunosuppression, central nervous system and other side effects. Compound prescriptions of Chinese medicine or plant extracts have more complex ingredients, unclear or low content, and are slower to take effect on the disease.
[0049] In the preparation of a rectal drug delivery system for the treatment of hemorrhoids, the rectal drug delivery system provided by the present application is locally administered, and it is possible to simultaneously load Chinese and Western medicines, and protect the drugs from interacting with each other, while using corresponding drugs for different courses of treatment of hemorrhoids. The first active ingredient of the drug selects a chemical drug with antibacterial, analgesic, and hemostatic effects. After the preparation is injected into the rectal part, the water-soluble film layer structure is quickly dissolved and released, which makes up for the defect of slow onset of Chinese medicine and provides analgesic and antibacterial effects. The middle layer O / W structure and the inner layer W / O structure load Chinese medicine, reduce the risk of side effects of chemical drugs, and achieve a long-acting sustained-release conditioning effect. In addition, the two layers of structures load different drugs and play a synergistic therapeutic role. The second active ingredient of the drug selects a drug with anti-inflammatory and detumescent effects, so as to deal with local inflammation, and the O / W matrix enables the drug to have a long-acting sustained-release effect to treat chronic inflammation. The third active ingredient of the drug selects a convergent and detumescent drug, so as to provide a consolidation effect after the middle layer drug completes the anti-inflammatory effect, shrinks the hemorrhoidal tissue swollen due to inflammation, and relieves anal discomfort.
[0050] In some embodiments, the rectal drug delivery system is used to prepare a systemic therapeutic drug.
[0051] In some embodiments, in the preparation of a rectal drug delivery system for pain treatment, the first active pharmaceutical ingredient includes at least one of caffeine, metoclopramide, pandoridone, clonidine, dexmedetomidine, acetaminophen, magnesium sulfate, dexamethasone, methylprednisolone, hydrocortisone and prednisone; the second active pharmaceutical ingredient includes at least one of aspirin, naproxen, diclofenac, ibuprofen, indomethacin, acetaminophen, rofecoxib, fentanyl, methadone, buprenorphine, codeine, carbamazepine, gabapentin, and pregabalin; and the third active pharmaceutical ingredient includes at least one of acetaminophen, sumatriptan, aspirin, ibuprofen, indomethacin, diclofenac, naproxen, rofecoxib, carbamazepine, gabapentin, and pregabalin.
[0052] Furthermore, in the preparation of a rectal drug delivery system for treating migraine, the first active pharmaceutical ingredient includes at least one of caffeine, metoclopramide, and pandoridone, the second active pharmaceutical ingredient includes at least one of aspirin, naproxen, diclofenac, and ibuprofen, and the third active pharmaceutical ingredient includes at least one of acetaminophen and sumatriptan.
[0053] Migraine is a common, recurrent headache disease characterized by severe throbbing headache on one or both sides, often accompanied by symptoms such as nausea, vomiting, and hypersensitivity to sound and light stimulation. The first-line treatment drugs are non-steroidal anti-inflammatory drugs or other simple analgesics, and antiemetics are used when necessary. The most common adverse reaction of non-steroidal anti-inflammatory drugs is gastrointestinal reaction. The rectal drug delivery system provided by the present invention can achieve slow and stable release of non-steroidal anti-inflammatory drugs, reducing the probability of side effects caused by excessive blood drug concentration in a short period of time.
[0054] In the preparation of a rectal drug delivery system for the treatment of migraine, the rectal drug delivery system of the present application is systemically administered, and can achieve continuous analgesia and treat migraine associated symptoms according to the properties of the compound drug. The first active ingredient is selected from auxiliary drugs for the treatment of migraine such as metoclopramide and pandolidones, which are used to quickly treat the nausea / vomiting symptoms associated with migraine, or caffeine is selected to enhance the efficacy of analgesics. The second active ingredient is selected from non-steroidal anti-inflammatory drugs such as aspirin, naproxen, diclofenac, and ibuprofen, and the O / W structure enables the drug to achieve a long-acting sustained release effect. The third active ingredient is selected from acetaminophen and sumatriptan to further enhance the therapeutic effect and avoid recurrence.
[0055] In some embodiments, the O / W emulsion matrix includes an oil-soluble matrix, a water-soluble matrix and an O / W emulsifier, and the mass ratio of the oil-soluble matrix, the water-soluble matrix and the O / W emulsifier in the O / W emulsion matrix is 1:(1.2-5):(0.01-0.2).
[0056] O / W emulsifiers are used to reduce the interfacial tension of the components in the O / W mixed system to form a stable O / W emulsion matrix. They can be a single component or a composite component with an HLB between 8-18.
[0057] In some embodiments, in the O / W structure, the oil-soluble base is selected from one or more of cocoa butter, palm kernel oil, palmitate, stearic acid, propylene glycol stearate and mixed fatty acid glycerides.
[0058] In some embodiments, in the O / W structure, the water-soluble matrix is selected from one or more of glycerol, gelatin and polyethylene glycol (PEG).
[0059] In some embodiments, in the O / W structure, the O / W emulsifier is selected from one or more of Tween, fatty alcohol polyoxyethylene ether, fatty acid polyoxyethylene ester and polyoxyethylene lauryl ether. Tween can be Tween 60 or Tween 80, and the fatty alcohol polyoxyethylene ether can be Peregal O-15 or Peregal O-20.
[0060] In some embodiments, the O / W emulsion matrix also includes a sustained-release agent, and the mass ratio of the oil-soluble matrix, the water-soluble matrix, the sustained-release agent and the O / W emulsifier in the O / W emulsion matrix is 1:(1.5-5):(0.01-0.5):(0.02-0.1); preferably 1:(1.5-3):(0.01-0.5):(0.02-0.1).
[0061] The sustained-release agent plays a role in regulating the release rate of the second active ingredient of the drug in the O / W structure, thereby achieving a long-term sustained-release effect.
[0062] In some embodiments, in the O / W structure, the sustained-release agent is a cellulose derivative selected from one or more of methyl cellulose (MC), hydroxyethyl cellulose (HEC) and hydroxypropyl methyl cellulose (HPMC).
[0063] In some embodiments, the W / O emulsion matrix includes an oil-soluble matrix, a water-soluble matrix and a W / O emulsifier, and the mass ratio of the oil-soluble matrix, the water-soluble matrix and the W / O emulsifier in the W / O emulsion matrix is 1:(0.1-0.9):(0.01-0.2).
[0064] W / O emulsifiers are used to reduce the interfacial tension of the components in the W / O mixed system to form a stable W / O emulsion matrix. They can be a single component or a composite component with an HLB value between 3-7.
[0065] In some embodiments, in the W / O structure, the oil-soluble base is selected from one or more of cocoa butter, palm kernel oil, palmitate, stearic acid, propylene glycol stearate and mixed fatty acid glycerides.
[0066] In some embodiments, in the W / O structure, the water-soluble matrix is selected from one or more of glycerol, gelatin and polyethylene glycol.
[0067] In some embodiments, in the W / O structure, the W / O emulsifier is selected from one or more of Span, glyceryl monolaurate, diethylene glycol monostearate, hydroxylated lanolin and glyceryl monostearate. The Span may be Span 60 or Span 80.
[0068] In some embodiments, the mass ratio of the first pharmaceutically active ingredient to the water-soluble material is 1:(1.5-20), including but not limited to 1:1.5, 1:3, 1:5, 1:10, 1:15, 1:20; preferably 1:(3-10).
[0069] In some embodiments, the mass ratio of the second pharmaceutically active ingredient to the O / W emulsion matrix is 1:(1-15), including but not limited to 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 1:11, 1:12, 1:13, 1:14, 1:15; preferably 1:(1-12).
[0070] In some embodiments, the mass ratio of the third pharmaceutically active ingredient to the W / O emulsion matrix is 1:(1-20), including but not limited to 1:1, 1:5, 1:10, 1:15, 1:20; preferably 1:(1-15).
[0071] In some of the embodiments, the mass ratio of the water-soluble film layer structure, the O / W structure and the W / O structure is 1:(10-20):(5-12).
[0072] The second aspect of the present application provides a method for preparing the rectal drug delivery system provided in the first aspect, such as Figure 1 As shown, the preparation method comprises the following steps:
[0073] S1. Premix the second active pharmaceutical ingredient and the O / W emulsion matrix, heat and melt them, and inject them into the mold 1. After cooling and solidification, extract the mold core 13 to obtain an O / W structure with an inner cavity.
[0074] S2. Premix the third active pharmaceutical ingredient and the W / O emulsion matrix, heat and melt them, add them into the inner cavity of the O / W structure, cool and solidify them to form a W / O structure, and then demold them to obtain an intermediate.
[0075] S3. Premix the first active pharmaceutical ingredient and the water-soluble material and then dissolve them in distilled water, or dissolve the water-soluble material in distilled water, and use the obtained coating solution to coat the intermediate obtained in step S2 to form a water-soluble film layer structure to obtain a rectal drug delivery system.
[0076] In some embodiments, in step S3, a film coater is used to coat the intermediate by intermittently spraying the coating liquid.
[0077] In some embodiments, the mold structure is as follows Figure 2 As shown, the mold 1 comprises an outer jacket 11, an injection port 12 and a mold core 13. The mold core 13 can be withdrawn.
[0078] In some embodiments, such as Figure 2 As shown, the mold 1 is torpedo-shaped, with a length of 2 cm, a diameter of the mold core 13 of 0.5 cm, and a width between the outer jacket 11 and the mold core 13 of 0.7 cm.
[0079] In some embodiments, in step S1 , the second pharmaceutically active ingredient and the O / W emulsion matrix are pre-mixed, heated and melted, and then injected into the mold 1 through the injection port 12 .
[0080] The embodiments of the present application will be described in detail below in conjunction with the examples. The raw materials used in the following examples are all commercially available products unless otherwise specified.
[0081] Examples 1 to 3
[0082] 1) Drug selection: The first active ingredient of the drug: caffeine; the second active ingredient of the drug: aspirin; the third active ingredient of the drug: acetaminophen. The specific formula is shown in Table 1 below:
[0083] Table 1: Components of the rectal drug delivery system in Examples 1 to 3
[0084]
[0085]
[0086] 1) Preparation of middle layer: The second active pharmaceutical ingredient aspirin, oil-soluble matrix mixed fatty acid glyceride, water-soluble matrix polyethylene glycol (PEG), sustained-release agent hydroxypropyl methylcellulose (HPMC) and O / W emulsifier Tween 80 are pre-mixed in the above-mentioned component amounts, heated to 40° C. to melt, and then injected into the main material port of the mold. After cooling to room temperature and keeping for 20 minutes, the inner core of the mold is pulled out to obtain an O / W structure with an inner cavity.
[0087] 2) Preparation of inner layer: pre-mix the third active ingredient acetaminophen, the oil-soluble matrix propylene glycol stearate, the water-soluble matrix gelatin and the W / O emulsifier Span 60 in the above-mentioned component amounts, heat to 40°C to melt, add the mixture into the inner cavity of the O / W structure prepared in the previous step, solidify to form a W / O structure and then demold to obtain an intermediate.
[0088] 3) Preparation of outer layer: prepare the first active ingredient caffeine, water-soluble materials hydroxypropyl methylcellulose (HPMC) and polyethylene glycol (PEG) according to 10 times the component amount, pre-mix them using a 200 rpm mixer, and then dissolve the mixture in 5000 parts by weight of distilled water to obtain a coating solution; use a film coating machine to coat the intermediate prepared in the previous step by intermittent spraying of the coating solution (spraying for 10 minutes, drying for 30 seconds) until the weight of the drug delivery system increases to 60 parts by weight, that is, the total weight of the components of the outer layer water-soluble film.
[0089] The dissolution of active pharmaceutical ingredients was checked using the basket method:
[0090] The medium was 500 mL of PBS buffer solution with a pH of 7.4, the rotation speed was 50 rpm, the temperature was 37±0.2°C, the sampling time was set to 5 min, 10 min, 15 min, 20 min, 30 min, 60 min, 3 h, 5 h, 7 h, 9 h, 12 h, 15 h, 17 h, 20 h, and 24 h, and 5 mL was sampled each time.
[0091] The cumulative dissolution is shown in Table 2. Figure 3 , Figure 4 and Figure 5 As shown:
[0092] Table 2: Cumulative dissolution of active pharmaceutical ingredients in each layer of the rectal drug delivery system in Examples 1 to 3
[0093]
[0094] From Table 2 and Figures 3 to 5 It can be seen that the active pharmaceutical ingredients of each layer in Examples 1 to 3 are released step by step within 24 hours, and the active pharmaceutical ingredients of each layer are basically released completely, which prolongs the action time of the drug delivery system and ensures the efficacy of the drug.
[0095] Embodiments 4 to 6
[0096] 1) Drug selection: The first active ingredient of the drug: lidocaine; the second active ingredient of the drug: phellodendron amurense extract; the third active ingredient of the drug: bletilla striata extract. The specific formula is shown in Table 3 below.
[0097] Table 3: Components of the rectal drug delivery system in Examples 4 to 6
[0098]
[0099] 2) Referring to the preparation methods of Examples 1 to 3, the formulations were prepared using the formula in Table 3 above. The drug loading of each layer structure of the drug delivery system is shown in Table 4 below.
[0100] Table 4: Drug loading of each layer structure of rectal drug delivery system in Examples 4 to 6
[0101] Outer layer (%) Middle layer (%) Inner layer (%) Example 4 8.3 22 16.7 Example 5 16.7 50 40 Example 6 25 50 50
[0102] It can be seen that the drug delivery system of the present invention improves the drug loading capacity of the rectal drug delivery system, especially the drug loading of the middle layer and the inner layer can be increased to 50%, thereby improving the technical defect of low drug loading of ordinary suppositories and achieving better therapeutic effects.
[0103] Example 7
[0104] Compared with Example 1, the middle layer O / W structure and the inner layer W / O structure are the same, and the preparation method of the preparation is also the same. The difference is that:
[0105] The outer water-soluble film structure of Example 1 is loaded with drugs, that is, includes the first active pharmaceutical ingredient. The outer water-soluble film structure of Example 7 is not loaded with drugs, that is, does not include the first active pharmaceutical ingredient. The specific formulas of the water-soluble film structures of Example 1 and Example 7 are shown in Table 5 below.
[0106] Table 5: Components of the water-soluble film structure of the rectal drug delivery system in Example 1 and Example 7
[0107]
[0108] The preparations obtained in Example 1 and Example 7 all maintained regular shapes without cracks or unevenness. The water-soluble film without drugs can prevent oxygen from directly contacting the middle layer O / W structure and the inner layer W / O structure, and has a protective effect on the drug and preparation structure. It was found during use that the water-soluble film layer structure made of water-soluble materials can also dissolve quickly, without causing the patient to feel a foreign body.
[0109] Example 8
[0110] Compared with Example 3, the selection of active pharmaceutical ingredients, the middle layer O / W structure and the inner layer W / O structure of the two examples are the same, and the difference is that:
[0111] The outer water-soluble film structure in Example 8 further includes a release promoter, which is sodium dodecyl sulfate (SDS). The specific formulas of the water-soluble film structures in Examples 3 and 8 are shown in Table 6 below.
[0112] Table 6: Components of the water-soluble film structure of the rectal drug delivery system in Example 3 and Example 8
[0113]
[0114] The inner layer structure and the middle layer structure of the drug delivery system were prepared in the same manner as in Example 3. 1 part by weight of the release enhancer SDS was added to the mixture of the outer layer structure to obtain the corresponding drug delivery system. The dissolution test of the first active ingredient of the outer water-soluble film layer structure was performed. The test results are shown in Tables 7 and 8 below. Figure 6 .
[0115] Table 7: Cumulative dissolution of the first active pharmaceutical ingredient in the outer layer of the rectal drug delivery system in Examples 3 and 8
[0116]
[0117]
[0118] As shown in Table 7 and Figure 6As shown, by comparing Example 3 and Example 8, it can be seen that after adding the release enhancer SDS, the release rate of the outermost water-soluble film structure increases, and the drug release time is shortened from 60 minutes when no release enhancer is added to 30 minutes.
[0119] Example 9
[0120] 1) Drug selection: The first active ingredient, the second active ingredient, and the third active ingredient are all selected as acetaminophen, and the specific formula is shown in Table 8 below:
[0121] Table 8: Components of the rectal drug delivery system in Example 9
[0122]
[0123] The content of the active ingredient of Example 9 was tested by the same dissolution method as in Examples 1 to 3. The cumulative dissolution is shown in Table 9 and Figure 7 shown.
[0124] Table 9: Cumulative dissolution of acetaminophen in the rectal administration system of Example 9
[0125]
[0126]
[0127] Embodiments 10 to 11
[0128] The drugs selected in Example 10 are pramoxine, Sophora japonica extract and Galla chinensis extract.
[0129] The drugs selected for Example 11 are metoclopramide, diclofenac and sumatriptan.
[0130] The specific formulations of Examples 10 to 11 are shown in Table 10 below.
[0131] Table 10: Components of the rectal drug delivery system in Examples 10-11
[0132]
[0133] The dissolution test of the active pharmaceutical ingredients of Examples 10 to 11 was carried out according to the same dissolution method as in Examples 1 to 3, and the cumulative dissolution is shown in Table 11 below.
[0134] Table 11: Cumulative dissolution of active pharmaceutical ingredients in each layer of the rectal drug delivery system in Examples 10 to 11
[0135]
[0136] Comparative Example 1: Oil-soluble matrix suppository
[0137] Drug group: 10 parts by weight of caffeine, 50 parts by weight of aspirin, and 40 parts by weight of acetaminophen.
[0138] Matrix group: 1000 parts by weight of mixed fatty acid glycerides.
[0139] After premixing the drugs, add them into the molten matrix at 40°C, mix them evenly and inject them into a common suppository mold.
[0140] The cumulative dissolution rate of the drug in Comparative Example 1 was tested using the same dissolution method as in Examples 1 to 3. The results are shown in Table 12.
[0141] Table 12: Cumulative dissolution of each drug in Comparative Example 1
[0142]
[0143] As shown in Table 12, Comparative Example 1 has no progressive release effect, and all three drugs are dissolved within 20 minutes, and the long-acting sustained-release therapeutic effect cannot be achieved. In addition, the melting speed of the oil-soluble matrix suppository is too fast, the touch is greasy, the patient's use experience is not good, and the compliance is poor.
[0144] Comparative Example 2: Water-soluble matrix suppository
[0145] Drug group: 100 parts by weight of Phellodendron amurense extract.
[0146] Matrix group: 350 parts by weight of polyethylene glycol.
[0147] After premixing the drugs, add them into the molten matrix at 40°C, mix them evenly and inject them into a common suppository mold.
[0148] Compared with Example 4, when the ratio of the drug combination matrix group was the same, it was found that the drug was easy to settle and unevenly distributed during the preparation of the single matrix preparation.
[0149] The technical features of the above-described embodiments may be arbitrarily combined. To make the description concise, not all possible combinations of the technical features in the above-described embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.
[0150] The above-mentioned embodiments only express several implementation methods of the present invention, and the descriptions thereof are relatively specific and detailed, but they cannot be understood as limiting the scope of the invention patent. It should be pointed out that, for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present invention, and these all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims.
Claims
1. A rectal drug delivery system, It is characterized in that It includes a water-soluble film layer structure located in the outer layer, an O / W structure located in the middle layer, and a W / O structure located in the inner layer; The water-soluble film layer structure includes a water-soluble material; The O / W structure includes a second active pharmaceutical ingredient and an O / W emulsion matrix; The W / O structure includes a third pharmaceutically active ingredient and a W / O emulsion matrix.
2. The rectal drug delivery system according to claim 1, It is characterized in that The water-soluble film layer structure further includes a first active pharmaceutical ingredient, and the mass ratio of the first active pharmaceutical ingredient to the water-soluble material is 1:(1.5-20).
3. The rectal drug delivery system according to claim 2, It is characterized in that The water-soluble film layer structure also includes a release promoter, and the weight ratio of the release promoter to the first active pharmaceutical ingredient in the water-soluble film layer structure is (0.03-0.1):
1.
4. The rectal drug delivery system according to claim 2, It is characterized in that The rectal drug delivery system is used in preparing systemic therapeutic drugs or local therapeutic drugs.
5. The rectal drug delivery system according to claim 4, It is characterized in that The first active pharmaceutical ingredient comprises at least one of polymyxin B, benzocaine, lidocaine, pramoxine, indomethacin, furazolidone, caffeine, metoclopramide, pandoridone, clonidine, dexmedetomidine, acetaminophen, magnesium sulfate, dexamethasone, methylprednisolone, hydrocortisone and prednisone; The second active pharmaceutical ingredient includes at least one of Sophora japonica, Fructus Aurantii Immaturus, Cortex Phellodendri, Bezoar, aspirin, naproxen, diclofenac, ibuprofen, indomethacin, acetaminophen, rofecoxib, fentanyl, methadone, buprenorphine, codeine, carbamazepine, gabapentin, and pregabalin; The third active pharmaceutical ingredient includes at least one of Bletilla striata, Galla chinensis, Ampelopsis pilosula, acetaminophen, sumatriptan, aspirin, ibuprofen, indomethacin, diclofenac, naproxen, rofecoxib, carbamazepine, gabapentin and pregabalin.
6. The rectal drug delivery system according to claim 1, It is characterized in that The O / W emulsion matrix comprises an oil-soluble matrix, a water-soluble matrix and an O / W emulsifier, and the mass ratio of the oil-soluble matrix, the water-soluble matrix and the O / W emulsifier in the O / W emulsion matrix is 1:(1.2-5):(0.01-0.2); and / or, The W / O emulsion matrix includes an oil-soluble matrix, a water-soluble matrix and a W / O emulsifier, and the mass ratio of the oil-soluble matrix, the water-soluble matrix and the W / O emulsifier in the W / O emulsion matrix is 1:(0.1-0.9):(0.01-0.2).
7. The rectal drug delivery system according to claim 6, It is characterized in that The O / W emulsion matrix also includes a sustained-release agent, and the mass ratio of the oil-soluble matrix, the water-soluble matrix, the sustained-release agent and the O / W emulsifier in the O / W emulsion matrix is 1:(1.5-5):(0.01-0.5):(0.02-0.1).
8. The rectal drug delivery system according to any one of claims 1 to 7, It is characterized in that The mass ratio of the second active pharmaceutical ingredient to the O / W emulsion matrix is 1:(1-15); and / or, The mass ratio of the third active pharmaceutical ingredient to the W / O emulsion matrix is 1:(1-20).
9. The rectal drug delivery system according to any one of claims 1 to 8, It is characterized in that The mass ratio of the water-soluble film layer structure, the O / W structure and the W / O structure is 1:(10-20):(5-12).
10. A method for preparing the rectal drug delivery system according to any one of claims 2 to 9, It is characterized in that The following steps are involved: The second active pharmaceutical ingredient and the O / W emulsion matrix are premixed, heated and melted, and then injected into a mold, and the inner core of the mold is extracted after cooling and solidification to obtain an O / W structure with an inner cavity; Premixing the third active pharmaceutical ingredient and the W / O emulsion matrix, heating and melting, and adding the mixture into the inner cavity of the O / W structure, cooling and solidifying to form the W / O structure, and then demolding to obtain an intermediate; The first active pharmaceutical ingredient and the water-soluble material are premixed and dissolved in distilled water, Alternatively, the water-soluble material is dissolved in distilled water, and the obtained coating solution is used to coat the intermediate. The water-soluble film layer structure is formed to obtain the rectal drug delivery system.
